targeted agents in NSCLC. Afatinib is FDA approved under the brand name Gilotrif for the first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution
Search Results
NCCN News
Lymphoma 101: The Plot Thickens
Presented by: Leo I. Gordon
RECIL criteria clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations. “These criteria still have to be worked out and haven’t been used quite as much in clinical trials as the
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
Presented by: Brian T. Hill
pirtobrutinib in this patient population “robust.” In summary, the treatment of CLL with targeted agents as initial therapy results in tremendous outcomes for most patients with prolonged disease control. In contrast to the prior era, we anticipate seeing more
Prostate Cancer, Version 1.2014
James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho
. Most patients with castration-recurrent or -resistant prostate cancer (CRPC) die of bone metastases and related complications. The recently approved radium-223 is the first bone-targeting agent to demonstrate a survival benefit in these patients
Impact of the 7th Edition AJCC Staging Classification on the NCCN Clinical Practice Guidelines in Oncology for Gastric and Esophageal Cancers
Vivian E. Strong, Thomas A. D’Amico, Lawrence Kleinberg, and Jaffer Ajani
esophageal staging. These histologies were originally grouped together because the prognosis seemed similar, but with the introduction of novel chemotherapy agents and targeted agents, treatment strategies by stage will likely diverge. For example, when
Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary
Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein, and Yanis Boumber
-trastuzumab emtansine and lapatinib have been approved (NCCN Guidelines for Breast Cancer). 1 Given the central role of targeted agents in the management of patients with tumors harboring these types of changes, testing for genomic alterations is recommended as part of
Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer
Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris
critical pathways in tumorigenesis have identified potentially targetable molecular mutations in a number of cancers. As a result, a number of studied targeted agents have demonstrated antitumor activity in preclinical models of thyroid cancer. 5 – 7
Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia
Presented by: Eunice S. Wang
chemoresistance, Dr. Wang noted. Numerous oral tyrosine kinase inhibitors against FLT3 (also known as FLT3-TKIs) are in development. The first-generation FLT3-TKIs (lestaurtinib, midostaurin, sorafenib) are multikinase targeted agents that were repurposed as
Treatment of Stage IV Colon Cancer in the United States: A Patterns-of-Care Analysis
Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton
Background De novo stage IV colon cancer accounts for approximately 22% of new cases of colon cancer and has an overall 5-year survival of approximately 14%. 1 The development of novel targeted agents and their use in combination with chemotherapy
New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma
Christopher A. Barker and April K. Salama
Advanced Disease With the approval of PD-1 checkpoint inhibitors and targeted agents for first-line treatment of advanced/metastatic disease, the direction for second-line therapy is less certain because most of the data for these agents come from studies